MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)

NCT00518739 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: MK2461

Sponsor

Merck Sharp & Dohme LLC